Identification of mRNA for 5-HT1 and 5-HT2 receptor subtypes in human coronary arteries

被引:44
|
作者
Ishida, T [1 ]
Hirata, K [1 ]
Sakoda, T [1 ]
Kawashima, S [1 ]
Akita, H [1 ]
Yokoyama, M [1 ]
机构
[1] Kobe Univ, Sch Med, Dept Internal Med 1, Chuo Ku, Kobe, Hyogo 6500017, Japan
关键词
human coronary artery; serotonin; 5-MT1B receptor; 5-MT2A receptor; ribonuclease protection assay;
D O I
10.1016/S0008-6363(98)00162-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Although pharmacological studies have indicated that serotonin (5-HT)-evoked contraction of the human coronary artery is mediated by 5-HT1-like and 5-HT2 receptors, the gene expression of 5-HT receptors is still unclear. We examined mRNA expression of 5-HT1 and 5-HT2 receptor subtypes in human coronary arteries. Methods: Total RNA was extracted from human coronary arteries of 14 patients at autopsy by the guanidine method. Reverse transcription-polymerase chain reaction (RT-PCR) and ribonuclease protection assays were performed to identify 5-HT1 and 5-HT2 receptor mRNA expression in human coronary artery. Results: By RT-PCR, 5-HT1B, 5-HT2A and 5-HT2B mRNAs were detected in all of the 14 patients. 5-HT1A, 5-HT1D, and 5-HT1E mRNAs were detected in only some patients. However, neither 5-HT1F, mRNA nor 5-HT2C mRNA was detected in any patient. By ribonuclease protection assay, 5-HT1B and 5-HT2A signals were detected in all patients examined, but neither 5-HT1A, 5-HT1D nor 5-HT2B signal was detected in any patient. Conclusions: Of 5-HT1/2 receptor subtypes, 5-HT1B and 5-HT2A receptor mRNAs were predominantly expressed in human coronary arteries. Our finding provides molecular evidence that the 5-HT1B receptor may be the 5-HT1-like receptor which mediates constriction of human coronary arteries. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:267 / 274
页数:8
相关论文
共 50 条
  • [1] IDENTIFICATION AND CLASSIFICATION OF 5-HT1 RECEPTOR SUBTYPES
    GOTHERT, M
    SCHLICKER, E
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1990, 15 : S1 - S7
  • [2] SIGNIFICANCE OF 5-HT1 AND 5-HT2 RECEPTOR SUBTYPES THAT MEDIATE CONTRACTIONS OF THE HUMAN ISOLATED CORONARY-ARTERY - EFFECT OF ANTIMIGRAINE DRUGS
    BAX, WA
    BOS, E
    SAXENA, PR
    CIRCULATION, 1993, 88 (04) : 192 - 192
  • [3] Characteristics of contractile 5-HT receptors in isolated human omental arteries: Presence of 5-HT1 and 5-HT2 receptors
    Wallerstedt, SM
    Tornebrandt, K
    Bodelsson, M
    PHARMACOLOGY & TOXICOLOGY, 1996, 78 (01): : 50 - 54
  • [4] CLONING OF THE HUMAN SEROTONIN 5-HT2 AND 5-HT1C RECEPTOR SUBTYPES
    SALTZMAN, AG
    MORSE, B
    WHITMAN, MM
    IVANSHCHENKO, Y
    JAYE, M
    FELDER, S
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 181 (03) : 1469 - 1478
  • [5] EVIDENCE THAT SPINAL 5-HT1, 5-HT2 AND 5-HT3 RECEPTOR SUBTYPES MODULATE RESPONSES TO NOXIOUS COLORECTAL DISTENSION IN THE RAT
    DANZEBRINK, RM
    GEBHART, GF
    BRAIN RESEARCH, 1991, 538 (01) : 64 - 75
  • [6] Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors
    Watson, J
    Brough, S
    Coldwell, MC
    Gager, T
    Ho, M
    Hunter, AJ
    Jerman, J
    Middlemiss, DN
    Riley, GJ
    Brown, AM
    BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 (07) : 1413 - 1420
  • [7] Diversity of 5-HT1 and 5-HT2 receptor subtypes examined by electrophysiological studies in rat dorsolateral septal nucleus.
    Hasuo, H
    Matsuoka, T
    Akasu, T
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2003, 91 : 56P - 56P
  • [8] Pharmacological characterisation of human 5-HT2 receptor subtypes
    Jerman, JC
    Brough, SJ
    Gager, T
    Wood, M
    Coldwell, MC
    Smart, D
    Middlemiss, DN
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 414 (01) : 23 - 30
  • [9] 5-HT1 AND 5-HT2 BINDING CHARACTERISTICS OF SOME QUIPAZINE ANALOGS
    GLENNON, RA
    SLUSHER, RM
    LYON, RA
    TITELER, M
    MCKENNEY, JD
    JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (11) : 2375 - 2380
  • [10] Differential effects of 5-HT1 and 5-HT2 receptor agonists on hindlimb movements in paraplegic mice
    Landry, ES
    Guertin, PA
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2004, 28 (06): : 1053 - 1060